These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33788377)

  • 1. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.
    Perakakis N; Stefanakis K; Feigh M; Veidal SS; Mantzoros CS
    Liver Int; 2021 Aug; 41(8):1853-1866. PubMed ID: 33788377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
    BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
    Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.
    Nestor JJ; Parkes D; Feigh M; Suschak JJ; Harris MS
    Sci Rep; 2022 Apr; 12(1):6666. PubMed ID: 35461369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM; Verschuren L; Caspers MPM; Worms N; Menke AL; Princen HMG
    Sci Rep; 2021 Mar; 11(1):5050. PubMed ID: 33658534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet.
    Somm E; Montandon SA; Loizides-Mangold U; Gaïa N; Lazarevic V; De Vito C; Perroud E; Bochaton-Piallat ML; Dibner C; Schrenzel J; Jornayvaz FR
    Transl Res; 2021 Jan; 227():75-88. PubMed ID: 32711187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway.
    Li Z; Feng PP; Zhao ZB; Zhu W; Gong JP; Du HM
    Biochem Biophys Res Commun; 2019 Feb; 510(1):20-26. PubMed ID: 30683312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
    Boeckmans J; Gatzios A; Heymans A; Rombaut M; Rogiers V; De Kock J; Vanhaecke T; Rodrigues RM
    Cells; 2022 Mar; 11(5):. PubMed ID: 35269515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitis.
    Choi YJ; Johnson JD; Lee JJ; Song J; Matthews M; Hellerstein MK; McWherter CA
    Am J Physiol Gastrointest Liver Physiol; 2024 Feb; 326(2):G120-G132. PubMed ID: 38014444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
    Briand F; Heymes C; Bonada L; Angles T; Charpentier J; Branchereau M; Brousseau E; Quinsat M; Fazilleau N; Burcelin R; Sulpice T
    Clin Transl Sci; 2020 May; 13(3):529-538. PubMed ID: 31981449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
    Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
    Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of thyroid hormone receptor-β improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis.
    Kannt A; Wohlfart P; Madsen AN; Veidal SS; Feigh M; Schmoll D
    Br J Pharmacol; 2021 Jun; 178(12):2412-2423. PubMed ID: 33655500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.